Earnings summaries and quarterly performance for Inspire Medical Systems.
Executive leadership at Inspire Medical Systems.
Timothy P. Herbert
Detailed
Chief Executive Officer, President, and Chair
CEO
BK
Bryan K. Phillips
Detailed
SVP, General Counsel, Chief Compliance Officer and Corporate Secretary
CW
Carlton W. Weatherby
Detailed
Chief Strategy and Growth Officer
JP
Jason P. Kelly
Detailed
Chief Manufacturing and Quality Officer
JC
John C. Rondoni
Detailed
Chief Product & Innovation Officer
MJ
Melissa J. Mann
Detailed
Chief People Officer
RA
Randall A. Ban
Detailed
Executive Vice President, Patient Access and Therapy Development
RJ
Richard J. Buchholz
Detailed
Chief Financial Officer
Board of directors at Inspire Medical Systems.
CM
Casey M. Tansey
Detailed
Director
CB
Cynthia B. Burks
Detailed
Director
DG
Dana G. Mead, Jr.
Detailed
Director
GL
Gary L. Ellis
Detailed
Lead Independent Director
GG
Georgia Garinois-Melenikiotou
Detailed
Director
MJ
Myriam J. Curet, M.D.
Detailed
Director
ST
Shawn T McCormick
Detailed
Director
SG
Shelley G. Broader
Detailed
Director
Research analysts who have asked questions during Inspire Medical Systems earnings calls.
Adam Maeder
Piper Sandler Companies
6 questions for INSP
Also covers: ABT, AXNX, EW +13 more
AP
Anthony Petrone
Mizuho Group
6 questions for INSP
Also covers: ADMA, ALC, AXGN +24 more
Brett Fishbin
KeyBanc Capital Markets
6 questions for INSP
Also covers: ALC, COO, ICUI +7 more
DR
David Rescott
Baird
6 questions for INSP
Also covers: HAE, IRTC, LIVN +7 more
RN
Richard Newitter
Truist Securities
6 questions for INSP
Also covers: AXNX, BBNX, DXCM +19 more
Travis Steed
Bank of America
6 questions for INSP
Also covers: ABT, AXNX, BAX +24 more
DA
Danielle Antalffy
UBS Group AG
5 questions for INSP
Also covers: ABT, ATRC, BAX +15 more
LB
Larry Biegelsen
Wells Fargo & Company
5 questions for INSP
Also covers: ABT, ALC, AXNX +25 more
MS
Michael Sarcone
Jefferies
5 questions for INSP
Also covers: ALC, ALGN, AXGN +12 more
Jonathan Block
Stifel Financial Corp.
4 questions for INSP
Also covers: ALGN, COO, CUTR +11 more
RM
Robert Marcus
JPMorgan Chase & Co.
4 questions for INSP
Also covers: ABT, BAX, BDX +21 more
SS
Shagun Singh Chadha
RBC Capital Markets
4 questions for INSP
Also covers: AXNX, BDX, DXCM +12 more
Chris Pasquale
Nephron Research LLC
3 questions for INSP
Also covers: ALC, AXGN, BSX +9 more
Christopher Pasquale
Nephron Research
3 questions for INSP
Also covers: ALC, AXGN, BSX +12 more
Michael Polark
Wolfe Research
3 questions for INSP
Also covers: BBNX, BSX, DXCM +13 more
Mike Kratky
Leerink Partners
3 questions for INSP
Also covers: AXGN, DXCM, MDT +5 more
JB
Jon Block
Stifel, Nicolaus & Company, Incorporated
2 questions for INSP
Also covers: ALGN, BBNX, COO +8 more
Michael Kratky
Leerink Partners
2 questions for INSP
Also covers: AXGN, BBNX, DXCM +6 more
Patrick Wood
Morgan Stanley
2 questions for INSP
Also covers: ALC, BDX, BLCO +20 more
RM
Robbie Marcus
JPMorgan Chase & Co.
2 questions for INSP
Also covers: ABT, BAX, BDX +15 more
SS
Shagun Singh
RBC
2 questions for INSP
Also covers: GMED, TFX, TNDM
SK
Suraj Kalia
Oppenheimer & Co. Inc.
2 questions for INSP
Also covers: ABT, AORT, ATRC +14 more
BN
Brett Netson
Leerink Partners
1 question for INSP
DA
Danielle Antalffy
UBS
1 question for INSP
Also covers: ATRC, BAX, BBNX +11 more
DM
Daniel Markowitz
Evercore ISI
1 question for INSP
Also covers: GH, NTRA, RGEN +3 more
Kallum Titchmarsh
Morgan Stanley
1 question for INSP
Also covers: ATEC, AXNX, EMBC +6 more
LB
Lawrence Biegelsen
Wells Fargo
1 question for INSP
Also covers: ABT, ALC, BAX +16 more
Mike Polark
Wolfe Research, LLC
1 question for INSP
Also covers: BBNX, BSX, DXCM +6 more
Recent press releases and 8-K filings for INSP.
Inspire Medical Systems Reports Q4 2025 Results and Updates 2026 Guidance Amid Reimbursement Changes
INSP
Earnings
Guidance Update
Demand Weakening
- Inspire Medical Systems reported Q4 2025 revenue of $269 million, an increase of 12%, and full-year 2025 revenue of $912 million, an increase of 14%, with improved operating margins and positive operating income.
- For full-year 2026, the company revised its revenue guidance to $950 million-$1 billion (representing 4%-10% growth), and provided outlooks for net income per diluted share of $1.23-$1.81 and adjusted net income per diluted share of $1.85-$2.35.
- The coding for the Inspire 5 procedure transitioned to CPT code 64582 with a -52 modifier, which is estimated to reduce the professional fee by approximately 10%-50%, potentially influencing physicians' willingness to perform the procedure; the company is pursuing short-term initiatives to minimize this reduction and a long-term strategy for a new CPT code by January 1, 2028.
- The WISeR program, a government initiative requiring prior authorization for Medicare cases in six pilot states, has impacted Medicare patient procedures in the first quarter of 2026 due to technical challenges and denials.
Feb 11, 2026, 10:00 PM
Inspire Medical Systems Reports Q4 2025 Results and Revises 2026 Guidance
INSP
Earnings
Guidance Update
Product Launch
- Inspire Medical Systems reported Q4 2025 revenue of $269 million, a 12% increase, and full-year revenue of $912 million, up 14%, with full-year adjusted net income per diluted share of $2.42.
- The company revised its full-year 2026 revenue outlook to $950 million-$1 billion, representing 4%-10% growth, and expects adjusted net income per diluted share of $1.85-$2.35.
- This revised outlook is primarily due to coding uncertainty for the Inspire 5 procedure, which is transitioning to CPT code 64582 with a -52 modifier, potentially reducing the professional fee by 10%-50%.
- Inspire plans to mitigate this impact by working with stakeholders to minimize the reduction and is pursuing a new CPT code for Inspire 5, anticipated by January 1, 2028.
- Q1 2026 revenue is expected to be approximately flat to the prior year, influenced by coding uncertainty and the WISeR program.
Feb 11, 2026, 10:00 PM
Inspire Medical Systems Reports Q4 and Full Year 2025 Results, Revises 2026 Guidance Due to Coding Changes
INSP
Earnings
Guidance Update
Demand Weakening
- Inspire Medical Systems reported strong financial performance for Q4 2025, with revenue increasing 12% to $269 million and full year revenue up 14% to $912 million, contributing to full year adjusted net income per diluted share of $2.42.
- The company announced a clarification regarding the coding for its Inspire V procedure, transitioning to CPT code 64582 with a -52 modifier, which is estimated to reduce the professional fee by 10%-50% and may influence physicians' willingness to perform the procedure.
- Consequently, Inspire Medical Systems revised its full year 2026 revenue guidance to $950 million - $1 billion (4%-10% growth), with Q1 2026 revenue expected to be approximately flat to prior year and a net loss anticipated in Q1. The company is pursuing both short-term initiatives to minimize the fee reduction and a long-term plan to develop a new CPT code by January 1, 2028.
Feb 11, 2026, 10:00 PM
Inspire Medical Systems, Inc. Announces Q4 and Full Year 2025 Financial Results and 2026 Outlook
INSP
Earnings
Guidance Update
Share Buyback
- Inspire Medical Systems, Inc. reported strong financial results for Q4 2025, with revenue increasing 12% to $269.1 million and net income per diluted share of $4.66 (GAAP) or $1.65 (adjusted). For the full year 2025, revenue reached $912.0 million, a 14% increase, with $117.0 million in operating cash flow.
- The company issued full-year 2026 revenue guidance of $950 million to $1.0 billion, representing 4% to 10% growth, and adjusted net income per diluted share guidance of $1.85 to $2.35. This outlook incorporates the estimated impact of coding uncertainty and the transition to CPT code 64582 with a -52 modifier.
- The launch of the Inspire V system is complete, and it received FDA approval for 3.0T MRI compatibility. Additionally, Inspire completed $175 million in share repurchases for the full year 2025.
Feb 11, 2026, 9:32 PM
Inspire Medical Systems, Inc. Announces Preliminary Q4 and Full Year 2025 Results, 2026 Guidance, and New CFO
INSP
Earnings
Guidance Update
CFO Change
- Inspire Medical Systems, Inc. announced preliminary, unaudited revenue for Q4 2025 between $268.9 million and $269.1 million, an approximately 12% increase over Q4 2024, and full year 2025 revenue between $911.8 million and $912.0 million, a 14% increase over full year 2024.
- The company provided initial full year 2026 revenue guidance of $1,003 million to $1,013 million, representing a 10% to 11% increase over full year 2025. This outlook does not include any contribution from increased reimbursement at this time.
- Matt Osberg has been appointed as Executive Vice President and Chief Financial Officer, with a start date of January 19, 2026.
Jan 12, 2026, 10:04 PM
Inspire (INSP) Pre-Announces 2025 Revenue, Provides 2026 Guidance, and Announces New CFO
INSP
Guidance Update
Product Launch
CFO Change
- Inspire (INSP) pre-announced full-year 2025 revenue of approximately $912 million.
- The company issued initial revenue guidance for 2026 between $1.003 billion and $1.013 billion, reflecting 10%-11% growth, which excludes any contributions from increased reimbursement.
- The Inspire 5 neurostimulator system launch has been successful, with 100% of physicians trained and 90% of centers on the SleepSync program. The new system reduces procedure time to 30-45 minutes.
- Inspire is actively working with agencies to clarify reimbursement for the Inspire 5 procedure, asserting that 64568 best describes the procedure and is currently being billed.
- Matt Osberg will join Inspire as the new Chief Financial Officer later in January.
Jan 12, 2026, 5:45 PM
Inspire Medical Systems Provides 2025 Revenue Update and 2026 Guidance, Announces New CFO
INSP
Guidance Update
Product Launch
CFO Change
- Inspire pre-announced Q4 and full-year 2025 revenue and provided initial 2026 revenue guidance, which does not include any contributions from increased reimbursement.
- The Inspire V neurostimulator system launch has seen strong adoption, with 100% of physicians trained and reduced procedure times, contributing to significant momentum in Q4 2025.
- The company is actively working to clarify reimbursement for code 64568, which was billed for Inspire V procedures throughout 2025.
- Matt Osberg will join Inspire as the new CFO in late January.
- Inspire is developing future innovations, including Inspire VI for auto sleep detection and a dual-channel device to treat high BMI patients.
Jan 12, 2026, 5:45 PM
Inspire Pre-Announces 2025 Revenue, Provides 2026 Guidance, and Announces New CFO
INSP
Guidance Update
Product Launch
CFO Change
- Inspire pre-announced full-year 2025 revenue of approximately $912 million and provided initial 2026 revenue guidance of $1.003 billion to $1.013 billion, representing 10%-11% growth. This guidance does not include contributions from increased reimbursement.
- The Inspire 5 system has fully launched with high adoption rates, and the company is developing Inspire 6 as a software upgrade for auto sleep detection to improve therapy adherence.
- Inspire is actively working with relevant agencies to clarify reimbursement for the 64568 procedure code, which was billed and paid for Inspire 5 procedures throughout 2025.
- Matt Osberg will join Inspire as the new CFO later in January.
Jan 12, 2026, 5:45 PM
Inspire Medical Systems Announces Preliminary Q4 and Full Year 2025 Results and 2026 Guidance
INSP
Earnings
Guidance Update
Management Change
- Inspire Medical Systems, Inc. anticipates preliminary fourth quarter 2025 revenue to be between $268.9 million and $269.1 million, an approximate 12% increase over the same quarter of 2024.
- Preliminary full year 2025 revenue is expected to range from $911.8 million to $912.0 million, representing an approximate 14% increase over full year 2024.
- The company provided initial full year 2026 revenue guidance of $1,003 million to $1,013 million, which would be a 10% to 11% increase over full year 2025.
- Matt Osberg has been appointed as the new Executive Vice President and Chief Financial Officer, with a start date of January 19, 2026.
Jan 12, 2026, 11:45 AM
Inspire Medical Systems Faces Securities Fraud Lawsuit Following Stock Drop
INSP
Legal Proceedings
Guidance Update
Product Launch
- Inspire Medical Systems (INSP) is facing a class action lawsuit for securities fraud following a more than 32% stock drop on August 5, 2025.
- The lawsuit alleges the company failed to adequately prepare for the launch of its Inspire V device, resulting in significant delays in adoption and weak demand.
- On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by more than 80%.
- This disclosure caused the stock price to drop $42.04 per share, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025.
- Investors have until January 5, 2026, to ask the Court to be appointed to lead the case.
Jan 2, 2026, 2:07 PM
Quarterly earnings call transcripts for Inspire Medical Systems.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more